Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018-Reference-Cited by-同舟云学术

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

Published:2020-05-21 Issue:6 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Flamm Robert K.¹,Duncan Leonard R.¹,Hamed Kamal A.²^ORCID,Smart Jennifer I.²,Mendes Rodrigo E.¹,Pfaller Michael A.¹³

Affiliation:

1. JMI Laboratories, North Liberty, Iowa, USA

2. Basilea Pharmaceutica International Ltd., Basel, Switzerland

3. University of Iowa, Iowa City, Iowa, USA

Abstract

Ceftobiprole medocaril is an advanced-generation cephalosporin prodrug that has qualified infectious disease product status granted by the US FDA and is currently being evaluated in phase 3 clinical trials in patients with acute bacterial skin and skin structure infections (ABSSSIs) and in patients with Staphylococcus aureus bacteremia. In this study, the activity of ceftobiprole and comparators was evaluated against more than 7,300 clinical isolates collected in the United States from 2016 through 2018 from patients with skin and skin structure infections.

Funder

HHS | Biomedical Advanced Research and Development Authority

Basilea Pharmaceutica

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02566-19

Reference39 articles.

1. Epidemiology of Dermatitis and Skin Infections in United States Physicians’ Offices, 1993–2005

2. Increased US Emergency Department Visits for Skin and Soft Tissue Infections, and Changes in Antibiotic Choices, During the Emergence of Community-Associated Methicillin-Resistant Staphylococcus aureus